09 Aug Ray Therapeutics
Peter Francis, M.D., Ph.D., Chief Scientific Officer, Chief Medical Officer
Oct. 7 | 1:45pm | FLW Ballroom G
San Francisco, CA
(Private)
Ray Therapeutics is a late-stage preclinical biotechnology company pioneering optogenetic gene therapies for blinding retinal diseases. Founded in 2021 and based in San Francisco, the company raised $100 million in a Series A financing led by Novo Holdings in May 2023. Ray’s lead candidate RTx-015, an AAV gene therapy delivering a light-sensitive protein, is expected to enter clinical trials soon for retinitis pigmentosa. The company is also developing RTx-015 for other inherited retinal degenerations and RTx-021 for Stargardt macular dystrophy and geographic atrophy. With a strong syndicate backing and promising preclinical data, Ray aims to provide potentially first-in-class, mutation-agnostic vision restoration therapies for patients with few treatment options.
